-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

703. Adoptive Immunotherapy: Poster II

Adoptive Immunotherapy Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 6, 2015: 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Yaya Chu, PhD1*, Fangyu Lee1*, Janet Ayello, MS1*, Brian Hang1*, Melanie Zhang1*, Hing C. Wong2*, Dean A Lee, MD/PhD3* and Mitchell S. Cairo, MD1,4,5,6,7

1Pediatrics, New York Medical College, Valhalla, NY
2Altor Bioscience Corporation, Miramar, FL
3Pediatrics, MD Anderson Cancer Center, Houston, TX
4Medicine, New York Medical College, Valhalla, NY
5Microbiology and Immunology, New York Medical College, Valhalla, NY
6Cell Biology and Anatomy, New York Medical College, Valhalla, NY
7Pathology, New York Medical College, Valhalla, NY

Ryan Urak, MS*, ChingLam Wong, BS*, Wen-Chung Chang, MS*, Elizabeth E. Budde, MD, PhD, Christine Brown, PhD*, Sandra H. Thomas, PhD, Stephen J. Forman, MD and Xiuli Wang, PhD

Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

Yasmine van Caeneghem1*, Glenn Goetgeluk1*, Karin Weening1*, Greet Verstichel1*, Sarah Bonte1*, Tom Taghon1*, Georges Leclercq1*, Fritz Offner2, Hinrich Abken3*, Tessa Kerre, MD, PhD2* and Bart Vandekerkhove1*

1Department of Clinical chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium
2Hematology, Ghent University Hospital, Gent, Belgium
3Centre for Molecular Medicine Cologne, University Hospital of Cologne, Cologne, Germany

Misty Jenkins, PhD1*, Alex Davenport1*, Ryan Cross1*, Carmen Yong1*, David S. Ritchie, MD, PhD2, Joe Trapani1*, Michael Kershaw1*, Phil Darcy1* and Paul Neeson, PhD3,4,5*

1Peter MacCallum Cancer Centre, Melbourne, Australia
2Royal Melbourne Hospital, Parkville, Australia
3Sir Peter MacCallum Dept of Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
4Haematology and Immunology Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
5Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

Emily R. Levy1,2*, Robert N. Reger, B.S.1*, Mattias Carlsten, M.D., Ph.D.1* and Richard W. Childs, M.D.1

1National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
2Institute for Biomedical Sciences, George Washington University, Washington, DC

Folashade Otegbeye, MD, MPH1, Nathan Mackowski, BA2*, Evelyn Ojo, BS2*, Marcos De Lima, MD3 and David N. Wald, MD PhD4*

1University Hospitals, Case Medical Center, Cleveland, OH
2Case Western Reserve University, Cleveland, OH
3Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland
4Department of Pathology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

Enli Liu, MD, MS1*, Yijiu Tong1*, Gianpietro Dotti, MD2*, Barbara Savoldo, MD2*, Muharrem Muftuoglu1*, Kayo Kondo, PhD1*, Malini Mukherjee3*, Jordan S. Orange, MD, PhD4*, Catherine Sobieski1*, Abdullah Alsuliman1*, Hila Shaim, MD1*, Nobuhiko Imahashi, MD, PhD1*, Michael J. Keating, MD5, Chitra M. Hosing, MD1, Nina Shah, MD1, William Wierda, MD, PhD6, Richard Champlin, MD1, Elizabeth J. Shpall, MD1 and Katayoun Rezvani, MD PhD1

1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX
3Pediatrics-Human Immunobiology, Baylor College of Medicine, Houston, TX
4Center for Human Immunobiology, Texas Children's Hospital and Baylor College of Medicine, Houston, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX

Rie Kuroda, MD*, Shintaro Mase, MD*, Toshihiro Fujiki, MD*, Hideaki Maeba, MD, Raita Araki, MD*, Yasuhiro Ikawa, MD, PhD*, Masaki Fukuda, MD*, Shoichi Koizumi, MD*, Akihiro Yachie, MD, PhD* and Ryosei Nishimura, MD, PhD*

Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

Pietro Merli, MD1*, Giuseppina Li Pira, PhD1*, Valentina Bertaina, PhD1*, Matilde Sinibaldi, PhD1*, Barbarella Lucarelli, MD1*, Letizia Pomponia Brescia, MD1*, Giuseppe Palumbo, MD1*, Giuseppe Maria Milano, MD1*, Maria Teresa Romano, MD1*, Valentina Cirillo, PhD1*, Luisa Strocchio, MD1*, Irma Airoldi, PhD2*, Luciana Vinti, MD1*, Concetta Quintarelli, PhD3*, Lorenzo Moretta, MD1*, Annemarie Moseley, MD, PhD4*, Alice Bertaina, MD, PhD3 and Franco Locatelli, Prof, MD, PhD5*

1Ospedale Pediatrico Bambino Gesł, Rome, Italy
2Laboratorio di Oncologia, Istituto Giannina Gaslini, Genova, Italy
3Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesł, Rome, Italy
4Bellicum Pharmaceuticals, Houston, TX
5Oncoematologia Pediatrica, Ospedale Pediatrico Bambino Gesł, Rome, Italy

Alena A. Chekmasova, PhD*, Holly M. Horton, PhD, Tracy E. Garrett, BA*, John W. Evans, PhD*, Johanna Griecci, BS*, Amanda Hamel, BS*, Howard J. Latimer IV, BS*, Stacie L. Seidel, MA*, Byoung Y. Ryu, PhD, Michael Kuczewski, MS*, Christopher J. Horvath, DVM, MS, DACVP*, Kevin M. Friedman, PhD* and Richard A. Morgan, PhD*

bluebird bio, Inc, Cambridge, MA

*signifies non-member of ASH